Mettler-Toledo International Inc. (0K10.L)
USD 1085.39
(2.02%)
USD 1085.39
(2.02%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.08 Billion USD | 6.69% |
| 2022 | 1.11 Billion USD | 0.17% |
| 2021 | 1.11 Billion USD | 15.98% |
| 2020 | 960.32 Million USD | -0.29% |
| 2019 | 963.13 Million USD | 0.97% |
| 2018 | 953.87 Million USD | 3.33% |
| 2017 | 923.16 Million USD | 8.28% |
| 2016 | 852.59 Million USD | 3.99% |
| 2015 | 819.88 Million USD | -7.8% |
| 2014 | 889.2 Million USD | 3.82% |
| 2013 | 856.51 Million USD | 2.49% |
| 2012 | 835.69 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 303.54 Million USD | 0.27% |
| 2024 Q1 | 280.8 Million USD | 4.06% |
| 2023 Q3 | 263.57 Million USD | -4.45% |
| 2023 Q1 | 280.11 Million USD | 2.41% |
| 2023 Q4 | 269.86 Million USD | 2.39% |
| 2023 Q2 | 275.83 Million USD | -1.53% |
| 2023 FY | 1.08 Billion USD | -2.35% |
| 2022 FY | 1.11 Billion USD | 0.17% |
| 2022 Q3 | 277.48 Million USD | -3.05% |
| 2022 Q2 | 286.22 Million USD | 2.83% |
| 2022 Q1 | 278.34 Million USD | -3.37% |
| 2022 Q4 | 273.52 Million USD | -1.43% |
| 2021 Q3 | 283.01 Million USD | 0.48% |
| 2021 Q4 | 288.06 Million USD | 1.78% |
| 2021 Q1 | 261.02 Million USD | -6.9% |
| 2021 Q2 | 281.64 Million USD | 7.9% |
| 2021 FY | 1.11 Billion USD | 15.98% |
| 2020 Q2 | 233.13 Million USD | -5.11% |
| 2020 Q4 | 280.35 Million USD | 10.17% |
| 2020 FY | 960.32 Million USD | -0.29% |
| 2020 Q1 | 245.69 Million USD | -4.59% |
| 2020 Q3 | 254.48 Million USD | 9.16% |
| 2019 FY | 963.13 Million USD | 0.97% |
| 2019 Q4 | 257.51 Million USD | 0.63% |
| 2019 Q3 | 255.89 Million USD | 0.18% |
| 2019 Q2 | 255.44 Million USD | 0.75% |
| 2019 Q1 | 253.54 Million USD | 6.41% |
| 2018 Q1 | 249.13 Million USD | -1.62% |
| 2018 Q3 | 249.88 Million USD | -4.15% |
| 2018 FY | 953.87 Million USD | 3.33% |
| 2018 Q2 | 260.71 Million USD | 4.65% |
| 2018 Q4 | 238.27 Million USD | -4.65% |
| 2017 FY | 923.16 Million USD | 8.28% |
| 2017 Q2 | 240.59 Million USD | 8.47% |
| 2017 Q4 | 253.24 Million USD | 0.06% |
| 2017 Q3 | 253.1 Million USD | 5.2% |
| 2017 Q1 | 221.8 Million USD | -3.53% |
| 2016 Q4 | 229.91 Million USD | 0.4% |
| 2016 FY | 852.59 Million USD | 3.99% |
| 2016 Q3 | 229 Million USD | -3.59% |
| 2016 Q2 | 237.53 Million USD | 14.8% |
| 2016 Q1 | 206.91 Million USD | -7.01% |
| 2015 Q2 | 213.92 Million USD | 2.3% |
| 2015 Q3 | 215.57 Million USD | 0.77% |
| 2015 FY | 819.88 Million USD | -7.8% |
| 2015 Q1 | 209.11 Million USD | -8.31% |
| 2015 Q4 | 222.5 Million USD | 3.21% |
| 2014 Q4 | 228.07 Million USD | 1.04% |
| 2014 FY | 889.2 Million USD | 3.82% |
| 2014 Q1 | 210.59 Million USD | -6.09% |
| 2014 Q2 | 224.82 Million USD | 6.76% |
| 2014 Q3 | 225.72 Million USD | 0.4% |
| 2013 Q2 | 212.42 Million USD | 3.81% |
| 2013 Q3 | 215.21 Million USD | 1.31% |
| 2013 Q4 | 224.24 Million USD | 4.19% |
| 2013 FY | 856.51 Million USD | 2.49% |
| 2013 Q1 | 204.62 Million USD | -4.9% |
| 2012 FY | 835.69 Million USD | 0.0% |
| 2012 Q4 | 215.15 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| uniQure N.V. | 285.08 Million USD | -282.127% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -2146.072% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -8872.819% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -166.481% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -295.146% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -664.683% |
| Imunon, Inc. | 21.03 Million USD | -5080.065% |
| Dynavax Technologies Corporation | 219.14 Million USD | -397.109% |
| Editas Medicine, Inc. | 247.3 Million USD | -340.506% |
| FibroGen, Inc. | 398.11 Million USD | -173.638% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -141.554% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -2682.392% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 31.764% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 19.946% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | -105.93% |
| Verastem, Inc. | 92.08 Million USD | -1083.039% |
| Zoetis Inc. | 2.76 Billion USD | 60.601% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 77.186% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -376.382% |
| Homology Medicines, Inc. | 9.87 Million USD | -10931.797% |
| Nektar Therapeutics | 190.9 Million USD | -470.651% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -980.455% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -2338.915% |
| Perrigo Company plc | 1.52 Billion USD | 28.728% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -300.663% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 97.317% |
| Illumina, Inc. | 3.81 Billion USD | 71.43% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 89.376% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 46.937% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -802.882% |
| Waters Corporation | 943.51 Million USD | -15.461% |
| Biogen Inc. | 5.2 Billion USD | 79.07% |
| Evolus, Inc. | 189.75 Million USD | -474.091% |
| Adicet Bio, Inc. | 152.03 Million USD | -616.525% |
| bluebird bio, Inc. | 240.23 Million USD | -353.474% |
| Geron Corporation | 70.44 Million USD | -1446.528% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 39.48% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -154.738% |
| Myriad Genetics, Inc. | 600.1 Million USD | -81.535% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -97.509% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -7731.906% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 37.616% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 61.305% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 48.492% |
| OPKO Health, Inc. | 574.68 Million USD | -89.563% |
| Exelixis, Inc. | 1.58 Billion USD | 31.346% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -195.538% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -1853.853% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -128.69% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -39.739% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -263.957% |
| Blueprint Medicines Corporation | 722.86 Million USD | -50.705% |
| Insmed Incorporated | 949.26 Million USD | -14.762% |
| TG Therapeutics, Inc. | 198.47 Million USD | -448.88% |
| Incyte Corporation | 1.19 Billion USD | 8.493% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -4.348% |